Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
出版年份 2023 全文链接
标题
Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
作者
关键词
-
出版物
Applied Health Economics and Health Policy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-29
DOI
10.1007/s40258-023-00842-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CHEERS to Updated Guidelines for Reporting Health Economic Evaluations!
- (2022) Richard J. Willke et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
- (2022) Don Husereau et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
- (2022) Don Husereau et al. VALUE IN HEALTH
- Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
- (2022) Carlos Escobar Cervantes et al. PLoS One
- Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
- (2022) Ju Hee Choi et al. Frontiers in Cardiovascular Medicine
- Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
- (2022) Sabine Michelsen Raunbak et al. Pharmacoeconomics-Open
- Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India
- (2022) Rajeswari Aghoram et al. Value in Health Regional Issues
- Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations
- (2022) Zahra Goudarzi et al. Value in Health Regional Issues
- Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
- (2021) Hongtao Wei et al. BMC HEALTH SERVICES RESEARCH
- Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
- (2021) Valentina Lorenzoni et al. CLINICAL DRUG INVESTIGATION
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
- (2021) Jan Steffel et al. EUROPACE
- Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting
- (2021) Yue Wu et al. Frontiers in Cardiovascular Medicine
- Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
- (2021) Taru Hallinen et al. ClinicoEconomics and Outcomes Research
- Cost‐effectiveness of anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation in mainland China
- (2021) Hui Zhou et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
- (2021) Simone Rivolo et al. PLoS One
- Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
- (2021) Rini Noviyani et al. BMJ Evidence-Based Medicine
- Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
- (2020) Shu-Jie Dong et al. CLINICAL THERAPEUTICS
- Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
- (2020) Ching‐Yu Wang et al. CTS-Clinical and Translational Science
- Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge
- (2020) Giuseppe Lippi et al. International Journal of Stroke
- Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
- (2020) Kevin Bowrin et al. PLoS One
- Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
- (2020) Koen Degeling et al. PHARMACOECONOMICS
- Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
- (2020) Evelyn Walter et al. Expert Review of Pharmacoeconomics & Outcomes Research
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
- (2020) Ching-Yu Wang et al. PHARMACOECONOMICS
- Cost‐effectiveness of rivaroxaban versus warfarin in non‐valvular atrial fibrillation patients with chronic kidney disease in China
- (2020) Lin Liu et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
- (2020) Gregory A. Roth et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
- (2019) Piyameth Dilokthornsakul et al. Heart Lung and Circulation
- Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
- (2019) Ahmad S. Hersi et al. ANNALS OF SAUDI MEDICINE
- Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
- (2019) Lisa A. de Jong et al. PLoS One
- Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
- (2019) Masatsugu Hori et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
- (2019) Siok Shen Ng et al. THROMBOSIS RESEARCH
- Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
- (2018) Alexa R. Hospodar et al. American Journal of Cardiovascular Drugs
- Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
- (2018) Shoroq M. Altawalbeh et al. VALUE IN HEALTH
- Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function
- (2018) Jonathan Salcedo et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
- (2018) Thananan Rattanachotphanit et al. PHARMACOECONOMICS
- Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer’s Disease
- (2018) Estefanía Ruiz Vargas et al. STROKE
- Latin American Clinical Epidemiology Network Series – Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile
- (2017) Fernando Lanas et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function
- (2017) Inmaculada Hernandez et al. THROMBOSIS RESEARCH
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
- (2017) Marinus van Hulst et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
- (2016) Brian M. Salata et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
- (2016) Kostas Athanasakis et al. American Journal of Cardiovascular Drugs
- Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
- (2016) Chieh-Yu Liu et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
- (2016) Ying Jiao Zhao et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
- (2016) Elaine Nguyen et al. PHARMACOTHERAPY
- Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
- (2016) Anuj Shah et al. STROKE
- Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials
- (2016) Kengo Ayabe et al. Journal of the American Heart Association
- Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
- (2016) Taru Hallinen et al. SpringerPlus
- Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
- (2016) Xue Li et al. PLoS One
- Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
- (2015) Elizabeth A. Magnuson et al. AMERICAN HEART JOURNAL
- Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
- (2015) Misericòrdia Carles et al. BMC HEALTH SERVICES RESEARCH
- Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
- (2015) Kostas Athanasakis et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
- (2015) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
- (2015) Isao Kamae et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
- (2015) Martin Krejczy et al. Biomed Research International
- Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
- (2014) Andreas Clemens et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
- (2014) Talitha I. Verhoef et al. American Journal of Cardiovascular Drugs
- Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
- (2014) Julie Chevalier et al. Archives of Cardiovascular Diseases
- Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
- (2014) Ye Wang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
- (2014) Thitima Kongnakorn et al. CLINICAL DRUG INVESTIGATION
- Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand
- (2014) Siriporn Jarungsuccess et al. CLINICAL THERAPEUTICS
- Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting
- (2014) Ying Zheng et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
- (2014) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
- (2014) P. Dorian et al. EUROPEAN HEART JOURNAL
- Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
- (2014) Carla Rognoni et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
- (2014) Alexander Mensch et al. PHARMACOECONOMICS
- Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
- (2014) Andrej Janzic et al. PHARMACOECONOMICS
- Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
- (2014) Torbjørn Wisløff et al. PHARMACOECONOMICS
- Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
- (2014) Jelena Stevanović et al. PLoS One
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
- (2014) Chia-Hsien Chang et al. THROMBOSIS RESEARCH
- Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
- (2014) João Morais et al. Revista Portuguesa de Cardiologia
- Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- (2014) T. Lanitis et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
- (2013) Yousif Ahmad et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting
- (2013) Bin Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
- (2013) William J. Canestaro et al.
- Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
- (2013) Carla Rognoni et al. CLINICAL DRUG INVESTIGATION
- Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis
- (2013) Joyce H. S. You JOURNAL OF GENERAL INTERNAL MEDICINE
- Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
- (2013) Martin Krejczy et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
- (2013) Joris Kleintjens et al. PHARMACOECONOMICS
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
- (2013) Brendan L. Limone et al. PLoS One
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) Amanda R. Harrington et al. STROKE
- Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
- (2013) M Pletscher et al. SWISS MEDICAL WEEKLY
- Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
- (2013) Doug Coyle et al. VALUE IN HEALTH
- Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
- (2013) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium
- (2013) Hanne Wouters et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
- (2012) Thomas Davidson et al. EUROPEAN HEART JOURNAL
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
- (2012) Anuraag R Kansal et al. HEART
- COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO WARFARIN FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION
- (2012) Soyon Lee et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
- (2012) H. Kamel et al. NEUROLOGY
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
- (2012) Hooman Kamel et al. STROKE
- Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada
- (2012) Michael Sharma et al. THROMBOSIS AND HAEMOSTASIS
- Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
- (2012) Lars K Langkilde et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
- (2011) Shimoli V. Shah et al. CIRCULATION
- The cost of illness of atrial fibrillation: a systematic review of the recent literature
- (2011) S. E. Wolowacz et al. EUROPACE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
- (2011) Anuraag Kansal et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now